Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.33 |
| ▸ | JAK1 | P23458 | 5/20 | 0.33 |
| ▸ | JAK3 | P52333 | 5/20 | 0.33 |
| ▸ | TYK2 | P29597 | 4/20 | 0.33 |
| ▸ | BTK | Q06187 | 14/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16610812 | 0.80 | — | — | |
| SCHEMBL16611035 | 0.78 | BTK (0.42) | BTK | |
| SCHEMBL25171837 | 0.76 | JAK2 (0.39) | JAK2JAK1JAK3TYK2BTK | |
| SCHEMBL18052593 | 0.76 | JAK2 (0.37) | JAK2JAK1JAK3TYK2BTK | |
| SCHEMBL16611171 | 0.75 | CA1 (0.47) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL16611927 | 0.69 | CFTR (0.32) | LDHA | |
| SCHEMBL16611256 | 0.65 | PIK3CD (0.37) | JAK2JAK1BTK | |
| SCHEMBL16611265 | 0.64 | MAP3K5 (0.30) | — | |
| SCHEMBL16623551 | 0.61 | JAK1 (0.34) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL16610849 | 0.61 | MEN1 (0.36) | JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | JAK2 1/4885JAK1 2/4885JAK3 11/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | JAK2 1/4885JAK1 2/4885JAK3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.